Valuation : Roche Holding AG

Market Cap 285B 353B 303B 260B 487B 33,348B 489B 3,382B 1,307B 17,077B 1,324B 1,295B 54,397B P/E 2026 *
19.9x
P/E 2027 * 17.6x
Enterprise Value 296B 366B 315B 270B 505B 34,618B 507B 3,511B 1,357B 17,728B 1,375B 1,345B 56,469B EV / Sales 2026 *
4.73x
EV / Sales 2027 * 4.42x
Free-Float
88.78%
Yield 2026 *
2.8%
Yield 2027 * 2.86%
Manager TitleAgeSince
Chief Executive Officer 51 2023-03-14
Director of Finance/CFO 59 2011-06-05
Chief Operating Officer - 2025-09-30
Director TitleAgeSince
Director/Board Member 68 1995-12-31
Chairman 59 2023-03-14
Director/Board Member 73 2015-03-02
Change 5-day change 1-year change 3-year change Capi.($)
-1.35%+2.01% - - 352B
-0.88%-2.15%+58.05%+105.26% 1,024B
-1.15%+2.68%+54.25%+74.19% 663B
-1.44%+0.38%+20.65%+76.13% 453B
-0.95%+0.23%+30.91%+37.78% 352B
-3.18%+1.78%+22.62%+41.55% 304B
+0.30%+0.67%+0.60%+11.25% 252B
-1.55%+1.11%+54.15%+75.59% 236B
+0.02%+2.24%-13.83%-55.80% 206B
-0.15%+3.65%+31.24%+103.39% 187B
Average -1.01%+1.26%+28.74%+52.15% 408.71B
Weighted average by Cap. -1.07%+0.62%+37.66%+66.90%

Financials

2026 *2027 *
Net sales 62.61B 77.41B 66.57B 57.16B 107B 7,321B 107B 742B 287B 3,749B 291B 284B 11,942B 65.43B 80.89B 69.57B 59.73B 112B 7,650B 112B 776B 300B 3,918B 304B 297B 12,479B
Net income 14.5B 17.92B 15.41B 13.23B 24.75B 1,695B 24.83B 172B 66.44B 868B 67.3B 65.83B 2,765B 16.32B 20.17B 17.35B 14.9B 27.86B 1,908B 27.95B 193B 74.78B 977B 75.76B 74.1B 3,112B
Net Debt 10.87B 13.43B 11.55B 9.92B 18.55B 1,271B 18.61B 129B 49.8B 651B 50.45B 49.35B 2,073B 4.02B 4.97B 4.27B 3.67B 6.86B 470B 6.88B 47.66B 18.42B 241B 18.66B 18.25B 767B
Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AA
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!